skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Search Icon Pharma Report StoreProduct loginProductLogin
Global Search Configuration

About William

USA

43+ years of experience

William_Looney_Pharma_Intelligence
William is an Executive Editor at Informa Pharma Intelligence with primary responsibility for biopharma industry-related coverage for its flagship feature-oriented online and monthly print publication, In Vivo. Principal areas of focus include global commercial strategy; C-suite issues and operations; market access; reputation; regulation and policy.
William is responsible for editorial content and serves as a thought leader in contacts between In Vivo and a wide variety of external organizations he has been involved with over the course of his career. Prior to joining In Vivo, he was Editor-in-Chief of Pharmaceutical Executive magazine, where he was recognized by the business media press for excellence in editorial commentary.  He also served in industry as a Director at Pfizer Inc., managing the company's public policy issue development and positioning outside the US and coordinating various external leadership activities for the CEO.  William began his career as a business analyst for the Economist Intelligence Unit of the UK Economist Group. 

Specialties

  • Biopharma Pipeline Strategy
  • Biotech
  • Commercial Strategy
  • Market Access
  • Policy & Regulation

William writes For

Analyst Articles

Articles by William

  • In Vivo

    ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

    By William Looney 27 Nov 2020

    ESG_In_2020_1

    The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

    Topic Financing Strategy

    View article